SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation.
COVID-19
SARS-CoV-2
antibodies
complement
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
12
2021
accepted:
07
06
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Antibodies specific for the spike glycoprotein (S) and nucleocapsid (N) SARS-CoV-2 proteins are typically present during severe COVID-19, and induced to S after vaccination. The binding of viral antigens by antibody can initiate the classical complement pathway. Since complement could play pathological or protective roles at distinct times during SARS-CoV-2 infection we determined levels of antibody-dependent complement activation along the complement cascade. Here, we used an ELISA assay to assess complement protein binding (C1q) and the deposition of C4b, C3b, and C5b to S and N antigens in the presence of antibodies to SARS-CoV-2 from different test groups: non-infected, single and double vaccinees, non-hospitalised convalescent (NHC) COVID-19 patients and convalescent hospitalised (ITU-CONV) COVID-19 patients. C1q binding correlates strongly with antibody responses, especially IgG1 levels. However, detection of downstream complement components, C4b, C3b and C5b shows some variability associated with the subject group from whom the sera were obtained. In the ITU-CONV, detection of C3b-C5b to S was observed consistently, but this was not the case in the NHC group. This is in contrast to responses to N, where median levels of complement deposition did not differ between the NHC and ITU-CONV groups. Moreover, for S but not N, downstream complement components were only detected in sera with higher IgG1 levels. Therefore, the classical pathway is activated by antibodies to multiple SARS-CoV-2 antigens, but the downstream effects of this activation may differ depending the disease status of the subject and on the specific antigen targeted.
Identifiants
pubmed: 35860286
doi: 10.3389/fimmu.2022.838780
pmc: PMC9289266
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Nucleoproteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Complement C1q
80295-33-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
838780Subventions
Organisme : British Heart Foundation
ID : CH/03/003/15571
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N023706/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W010011/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Lamerton, Marcial-Juarez, Faustini, Perez-Toledo, Goodall, Jossi, Newby, Chapple, Dietrich, Veenith, Shields, Harper, Henderson, Rayes, Wraith, Watson, Crispin, Drayson, Richter and Cunningham.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2021 Dec 20;12:759688
pubmed: 34987505
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Adv Exp Med Biol. 2021;1318:109-118
pubmed: 33973175
Cell Res. 2010 Jan;20(1):34-50
pubmed: 20010915
J Clin Invest. 2020 Nov 2;130(11):6151-6157
pubmed: 32759504
Front Immunol. 2021 Feb 22;12:627579
pubmed: 33692801
Clin Immunol. 2021 May;226:108716
pubmed: 33774179
Front Cell Dev Biol. 2022 Feb 15;10:824851
pubmed: 35242762
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Sci Rep. 2020 Sep 14;10(1):14991
pubmed: 32929138
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Mol Biol. 2022 Jan 30;434(2):167332
pubmed: 34717971
J Clin Med. 2021 May 19;10(10):
pubmed: 34069355
Sci Adv. 2021 Oct 29;7(44):eabj8065
pubmed: 34714668
Pediatr Allergy Immunol. 2021 Jul;32(5):1125-1129
pubmed: 33724541
Front Immunol. 2021 Apr 29;12:671052
pubmed: 33995410
Nat Commun. 2020 Feb 12;11(1):851
pubmed: 32051408
J Immunol Methods. 2021 Jul;494:113046
pubmed: 33775672
Thorax. 2000 May;55(5):364-9
pubmed: 10770816
Nat Med. 2020 Oct;26(10):1609-1615
pubmed: 32747830
Trends Immunol. 2021 Feb;42(2):94-103
pubmed: 33402318
iScience. 2021 Nov 19;24(11):103215
pubmed: 34632327
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Immunol. 2020 Sep 15;205(6):1488-1495
pubmed: 32699160
Mol Immunol. 2011 Aug;48(14):1656-65
pubmed: 21757235
J Dent Res. 2021 Oct;100(11):1220-1227
pubmed: 34077690
J Infect. 2022 Apr;84(4):579-613
pubmed: 35016901
Blood. 2020 Oct 29;136(18):2080-2089
pubmed: 32877502
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25018-25025
pubmed: 32943538
Lancet Rheumatol. 2020 Dec;2(12):e764-e773
pubmed: 33015643
Antibodies (Basel). 2020 Oct 13;9(4):
pubmed: 33066119
Immunology. 2021 Sep;164(1):135-147
pubmed: 33932228
Vaccines (Basel). 2021 May 12;9(5):
pubmed: 34066016
J Infect. 2021 Apr;82(4):e29-e30
pubmed: 33373652
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Science. 2020 Nov 27;370(6520):1089-1094
pubmed: 33082295
Front Immunol. 2021 Nov 02;12:767981
pubmed: 34804055
bioRxiv. 2021 Feb 23;:
pubmed: 33655244
Mucosal Immunol. 2011 Nov;4(6):590-7
pubmed: 21937984
EBioMedicine. 2022 Jan;75:103788
pubmed: 34954658
Am Rev Respir Dis. 1991 May;143(5 Pt 1):1062-6
pubmed: 2024815
Nature. 2020 Dec;588(7836):146-150
pubmed: 32726800
EClinicalMedicine. 2020 Nov;28:100590
pubmed: 33173853
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Biochemistry. 2021 Jul 13;60(27):2153-2169
pubmed: 34213308
Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L748-59
pubmed: 17071722
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1304-1308
pubmed: 32897730
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
Front Immunol. 2021 Jul 05;12:714511
pubmed: 34290717
BMJ. 2021 Mar 23;372:n771
pubmed: 33757984
Cell. 2021 Oct 14;184(21):5432-5447.e16
pubmed: 34619077
J Immunol. 2022 Mar 15;208(6):1500-1508
pubmed: 35228262
Clin Immunol. 2020 Nov;220:108598
pubmed: 32961333
Signal Transduct Target Ther. 2022 Jan 5;7(1):8
pubmed: 34987150
J Exp Med. 2014 Aug 25;211(9):1893-904
pubmed: 25113975
BMJ Open Respir Res. 2021 Sep;8(1):
pubmed: 34561239
Virulence. 2022 Dec;13(1):215-224
pubmed: 35094639